Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002220 · ClinicalTrials.gov registry record · Phase 3
Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00002220 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 120 participants.
The verdict
NCT00002220, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of giving indinavir plus efavirenz plus adefovir dipivoxil to patients who have failed treatment with nelfinavir and patients who have never taken a protease inhibitor (PI). Effectiveness is measured by the number of patients who have a viral load (level of HIV in the blood) below 400 copies/ml after 48 weeks of treatment.
Interventions
- DRUG Levocarnitine
- DRUG Efavirenz
- DRUG Indinavir sulfate
- DRUG Adefovir dipivoxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002220
The ClinicalTrials.gov registry entry for NCT00002220 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Levocarnitine is the first listed.
NCT00002220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002220 about?
NCT00002220 is a clinical study titled "Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir". The purpose of this study is to compare the effectiveness of giving indinavir plus efavirenz plus adefovir dipivoxil to patients who have failed treatment with nelfinavir and patients who have never taken a protease inhibitor (PI). Effectiveness is measured by the number of patients who have a viral...
What is the current status of trial NCT00002220?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants.
What interventions are being tested in trial NCT00002220?
The interventions under investigation include: Levocarnitine (DRUG), Efavirenz (DRUG), Indinavir sulfate (DRUG), Adefovir dipivoxil (DRUG).
Who is sponsoring clinical trial NCT00002220?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.